On December 2, Sanyou and CGBio Inc. held a signing ceremony for their strategic partnership in Shanghai. The two companies reached a consensus on in-depth cooperation in orthopedic biomaterials, aiming to advance the clinical application of world-leading bone repair technologies in China and deliver more efficient and safer treatment solutions to Chinese patients.
Scope and Details of the Partnership
01
Exclusive Distribution Rights Secured for Chinese Mainland
Sanyou has secured six-year exclusive distribution rights to Novosis Recombinant Human Bone Morphogenetic Protein‑2 Biomaterial in Chinese Mainland, effective upon the product’s marketing approval. A breakthrough innovation in global orthopedic regenerative medicine, the product combines recombinant human bone morphogenetic protein (rhBMP-2) with the bone graft substitute carrier Bongros. It delivers potent osteoinductive and osteoconductive properties thanks to genetic engineering and a porous sustained-release structure. (Note: Johnson & Johnson holds distribution rights for the product across Southeast Asia.)
02
Technical Breakthroughs: Three Core Advantages
Novel formulation: rhBMP‑2 is manufactured using high-density fermentation of recombinant Escherichia coli. It achieves internationally leading purity and overcomes bottlenecks of conventional manufacturing processes.
Sustained-release technology: Leveraging the biomimetic porous structure of Bongros bone graft substitute (its pore size and porosity closely resemble human cancellous bone), the product enables gradient release of rhBMP‑2 to extend the therapeutic duration.
Clinical value: It significantly accelerates bone healing and lowers the risk of secondary surgery for applications including spinal fusion, complex fractures and bone defect repair, filling the gap in China’s market for high-end bone repair materials.
03
Channels and Collaborative R&D
Commercial footprint: The partnership will accelerate the clinical application of Novosis in orthopedics and related fields by leveraging Sanyou’s well-established sales network covering thousands of hospitals across China.
Local adaptation: Litian (Taicang) Biotechnology Co., Ltd., a joint venture of the two companies (66% owned by Sanyou), will participate actively in product process optimization to drive technical iteration and cost control and facilitate domestic substitution.
Significance of the Partnership
The partnership represents not only a two-way breakthrough in technology and market access, but also a vital strategic move for Sanyou to deepen its footprint in orthopedic regenerative medicine. By securing exclusive rights to the Novosis product, Sanyou completes its orthopedic regenerative medicine product portfolio and strengthens its differentiated competitiveness within the bone repair materials segment. Sanyou also transcends the business boundaries of conventional orthopedic implants and accelerates penetration into high value-added sectors backed by differentiated strengths of Novosis in high-end markets such as spinal fusion and complex fractures. More importantly, Sanyou is building an innovation ecosystem that features “introduction, assimilation, secondary development and clinical translation” through a collaborative model of “technical introduction and local adaptation”. This model sets a sustainable development pathway for industrial upgrading within China’s orthopedic device industry.
